Jung‐Fu Chen

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 164 citations

Bone Disease, Osteopathy, Loft Extension Study +10

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis

Jawl‐Shan Hwang, Lin-Show Chin, Jung‐Fu Chen et al. · Journal of Bone and Mineral Metabolism · 2010 · 32 citations

Bone Disease, Bone Health, Postmenopausal Osteoporosis +9

Status of bone strength and factors associated with vertebral fracture in postmenopausal women with type 2 diabetes

Fang‐Ping Chen, Sheng‐Fong Kuo, Yu‐Ching Lin et al. · Menopause The Journal of The North American Menopause Society · 2018 · 27 citations